Indium-111 is commonly used in
nuclear medicine diagnostic imaging by
radiolabeling targeted molecules or cells. During its radioactive decay, it emits low energy gamma (γ) photons which can be imaged using
planar or
single-photon emission computed tomography (SPECT) gamma cameras (primary energies (ε) of 171.3
keV (91%) and 245.4 keV (94%))[3]
Uses in nuclear medicine
When formulated as an 111InCl solution, it can be used to bind
antibodies,
peptides, or other molecular targeted proteins or other molecules, typically using a chelate to bind the radionuclide (in this case 111In) to the targeting molecule during the
radiosynthesis/
radiolabeling process, which is tailored to the desired product.
111In labeled antibodies
Ibritumomab Tiuxetan; Zevalin - For dosimetry estimates prior to
90Y immunotherapy for
lymphoma
111In
ProstaScint — PSMA antibody imaging of prostate cancer
Octreotide is an somatostatin receptor inhibitor pharmaceutical which binds with high affinity to somatostatin receptors 2 and 5, interfering with normal receptor function. It is used as a drug to treat several neuroendocrine tumors in which somatostatin receptors are overexpressed or overactive. Examples include:
Sympathoadrenal system tumors:
pheochromocytoma, neuroblastoma, ganglioneuroma, paraganglioma
^Takács, S.; Tárkányi, F.; Hermanne, A. (Dec 2005). "Validation and upgrading of the recommended cross-section data of charged particle reactions: Gamma emitter radioisotopes". Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms. 240 (4): 790–802.
doi:
10.1016/j.nimb.2005.06.209.
ISSN0168-583X.